Terms: = Prostate cancer AND SEPT5, HCDCREL-1, 5413, ENSG00000184702, Q99719, PNUTL1, H5
11 results:
1. Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8
Chang M; He Y; Liu C; Lin R; Huang X; Liang D; Zhang J; Lu Y
Int J Biol Sci; 2022; 18(16):6035-6051. PubMed ID: 36439885
[No Abstract] [Full Text] [Related]
2. Dual attention guided multiscale neural network trained with curriculum learning for noninvasive prediction of Gleason Grade Group from MRI.
Hu J; Shen A; Qiao X; Zhou Z; Qian X; Zheng Y; Bao J; Wang X; Dai Y
Med Phys; 2023 Apr; 50(4):2279-2289. PubMed ID: 36412164
[TBL] [Abstract] [Full Text] [Related]
3. Preparation of Titanocene-Gold Compounds Based on Highly Active Gold(I)-N-Heterocyclic Carbene Anticancer Agents: Preliminary in vitro Studies in Renal and prostate cancer Cell Lines.
Curado N; Giménez N; Miachin K; Aliaga-Lavrijsen M; Cornejo MA; Jarzecki AA; Contel M
ChemMedChem; 2019 Jun; 14(11):1086-1095. PubMed ID: 30924298
[TBL] [Abstract] [Full Text] [Related]
4. Bioactivity of arid region honey: an in vitro study.
Hilary S; Habib H; Souka U; Ibrahim W; Platat C
BMC Complement Altern Med; 2017 Mar; 17(1):177. PubMed ID: 28356100
[TBL] [Abstract] [Full Text] [Related]
5. A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.
Lu ZH; Kaliberov S; Sohn RE; Kaliberova L; Du Y; Prior JL; Leib DJ; Chauchereau A; Sehn JK; Curiel DT; Arbeit JM
Oncotarget; 2017 Feb; 8(7):12272-12289. PubMed ID: 28103576
[TBL] [Abstract] [Full Text] [Related]
6. Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.
Northup JR; Deutscher SL
Comb Chem High Throughput Screen; 2016; 19(5):370-7. PubMed ID: 27055748
[TBL] [Abstract] [Full Text] [Related]
7. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
Janakiram M; Chinai JM; Fineberg S; Fiser A; Montagna C; Medavarapu R; Castano E; Jeon H; Ohaegbulam KC; Zhao R; Zhao A; Almo SC; Sparano JA; Zang X
Clin Cancer Res; 2015 May; 21(10):2359-66. PubMed ID: 25549724
[TBL] [Abstract] [Full Text] [Related]
8. prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
Patel HD; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
J Urol; 2014 Mar; 191(3):629-37. PubMed ID: 24060641
[TBL] [Abstract] [Full Text] [Related]
9. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
Sun T; Mary LG; Oh WK; Freedman ML; Pomerantz M; Pienta KJ; Kantoff PW
Clin Cancer Res; 2011 Mar; 17(6):1546-52. PubMed ID: 21135144
[TBL] [Abstract] [Full Text] [Related]
10. Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents.
Newton-Northup JR; Figueroa SD; Deutscher SL
Comb Chem High Throughput Screen; 2011 Jan; 14(1):9-21. PubMed ID: 20958260
[TBL] [Abstract] [Full Text] [Related]
11. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
[TBL] [Abstract] [Full Text] [Related]
